ПАТОЛОГИЧЕСКАЯ АНАТОМИЯ ИНФЕКЦИИ, ВЫЗВАННОЙ SARS-COV-2

Обложка


Цитировать

Полный текст

Аннотация

Материалом для исследования послужили данные 80 аутопсий пациентов, страдавших инфекцией COVID-19. При помощи макро- и микроскопического исследований продемонстрированы особенности патологических процессов в различных органах. Полученные данные в сочетании со сведениями из литературы позволяют сделать выводы о закономерностях поражения внутренних органов и систем организма, а также высказать предположения об отдельных звеньях патогенеза COVID-19. Обсуждается танатогенез при данном заболевании и основные причины смерти, к которым относятся: острая сердечно-легочная недостаточность, острая почечная недостаточность, тромбоэмболия легочной артерии, шок с полиорганной недостаточностью и сепсис. Подчеркивается чрезвычайная важность проведения аутопсий, которые несут неоценимую информацию о морфологическом субстрате данной инфекции, тесно связанном с возможными клиническими проявлениями.

Об авторах

Е. А. Коган

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0002-1107-3753

д.м.н., проф., член-корр. РАЕН, зав. кафедрой патологической анатомии им. А. И. Струкова,

Москва

Россия

Ю. С. Березовский

ФГБНУ «Центральный научно-исследовательский институт туберкулеза»

Email: report-q@yandex.ru
ORCID iD: 0000-0001-5904-0021

зав. отделением патологической анатомии,

Москва

Россия

Д. Д. Проценко

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

Автор, ответственный за переписку.
Email: chief@medprint.ru
ORCID iD: 0000-0002-5851-2768

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Т. Р. Багдасарян

ФГБНУ «Центральный научно-исследовательский институт туберкулеза»

Email: cniit@ctri.ru
ORCID iD: 0000-0001-9910-1570

к.м.н., главный врач,

Москва

Россия

Е. М. Грецов

ФГБНУ «Центральный научно-исследовательский институт туберкулеза»

Email: gem2505@yandex.ru
ORCID iD: 0000-0002-2337-4692

врач-патологоанатом,

Москва

Россия

С. А. Демура

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0001-9717-5496

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Г. А. Демяшкин

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0001-8447-2600

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Д. В. Калинин

ФГБУ «Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского» Министерства здравоохранения Российской Федерации

Email: dmitry.v.kalinin@gmail.com
ORCID iD: 0000-0001-6247-9481

к.м.н., зав. патологоанатомическим отделением,

Москва

Россия

А. Д. Куклева

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0002-6690-3347

аспирант кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Э. В. Курилина

ФГБУ «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения Российской Федерации

Email: ellakurilina@yandex.ru
ORCID iD: 0000-0002-3208-534X

зав. отделением патологической анатомии,

Москва

Россия

Т. П. Некрасова

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0001-6376-9392

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Н. Б. Парамонова

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0001-5380-7113

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

А. Б. Пономарев

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0002-4242-5723

к.м.н., доц. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

С. Г. Раденска-Лоповок

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0002-4669-260X

д.м.н., проф. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Л. А. Семенова

ФГБНУ «Центральный научно-исследовательский институт туберкулеза»

Email: lu.kk@yandex.ru
ORCID iD: 0000-0002-1782-7763

к.м.н., старший научный сотрудник отдела патоморфологии, клеточной биологии и биохимии,

Москва

Россия

А. С. Тертычный

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Министерства здравоохранения Российской Федерации

ORCID iD: 0000-0001-5635-6100

д.м.н., проф. кафедры патологической анатомии им. А. И. Струкова,

Москва

Россия

Список литературы

  1. World Health Organization Coronavirus disease 2019 (COVID-19) situation report—51. World Health Organization, 2020. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200311-sitrep-51-covid-19.pdf?sfvrsnј1ba62e57_10
  2. Chan J. F., Yuan S., Kok K. H., To K. K., Chu H., Yang J., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. https://doi.org/10.1016/S0140-6736(20)30154-9
  3. Ghinai I., McPherson T. D., Hunter J. C., Kirking H. L., Christiansen D., et al. Illinois COVID-19 Investigation Team. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;S0140-6736(20)):30607–3. https://doi.org/10.1016/S0140-6736(20)30607-3
  4. Zhao D., Yao F., Wang L., Zheng L., Gao Y., Ye J., et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin. Infect. Dis. 2020;ciaa247. https://doi.org/10.1093/cid/ciaa247
  5. Xiong Y., Sun D., Liu Y., Fan Y., Zhao L., Li X., Zhu W. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Investig. Radiol. 2020. https://doi.org/10.1097/RLI.0000000000000674
  6. Park W. B., Kwon N. J., Choi S.J., Kang C. K., Choe P. G., Kim J. Y., et al. Virus isolation from the first patient with SARS-CoV-2 in Korea. J. Korean Med. Sci. 2020;35(7):e84. https://doi.org/10.3346/jkms.2020.35.e84
  7. Walls A. C., Park Y. J., Tortorici M. A., Wall A., McGuire A. T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180:1–12. https://doi.org/10.1016/j.cell.2020.02.058
  8. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10. https://doi.org/10.1016/j.cell.2020.02.052
  9. Finlay B. B., See R. H., Brunham R. C. Rapid response research to emerging infectious diseases: lessons from SARS. Nat. Rev. Microbiol. 2004;2(7):602–607.
  10. Wrapp D., Wang N., Corbett K. S., Goldsmith J. A., Hsieh C. L., Abiona O. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. https://doi.org/10.1126/science.abb2507
  11. Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N. G., Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 2020;176:104742. https://doi.org/10.1016/j.antiviral.2020.104742
  12. Perrella A., Trama U., Bernardi F. F., Russo G., Monastra L., Fragranza F., et al. Editorial — COVID-19, more than a viral pneumonia. European Review for Medical and Pharmacological Sciences. 2020;24:5183–5185.
  13. Aguiar D., Lobrinus J. A., Schibler M., Fracasso T., Lardi1 C. Inside the lungs of COVID-19 disease. International Journal of Legal Medicine. 2020;(134):1271–1274. https://doi.org/10.1007/s00414-020-02318-9
  14. Pomara C., Volti G. L., Cappello F. COVID-19 Deaths: Are We Sure It Is Pneumonia? Please, Autopsy, Autopsy, Autopsy! J. Clin. Med. 2020;9:1259. https://doi.org/10.3390/jcm9051259
  15. Cамсонова М. В., Михалева Л. М., Черняев А. Л., Мишнев О. Д., Крупнов Н. М. Патологическая анатомия легких при COVID-19: Атлас; под ред. О. В. Зайратьянца. М.—Рязань: Издательство ГУП РО «Рязанская областная типография», 2020.
  16. Katzenstein F.-L. Diagnostic atlas of non-neoplastic lung disease. A practical guide for surgical pathologist. New York, NY: Demos Medical Publishing, 2016.
  17. Costabel U., du Bois R. M., Egan J. J. (eds.) Diffuse Parenchymal Lung Disease. Prog. Respir. Res. 2007;36:1–10. https://doi.org/10.1159/000102577
  18. Wallace A.H., Simpson J., Hirani N. Spencer’s pathology of the lung. Vol. 1. Ed. Ph. Hasleton, D.B. Frieder. Acute lung injury. Cambridge: Cambridge University Press. 2013;1:342–365.
  19. Jain A. COVID-19 and lung pathology. Indian J. Pathol. Microbiol. 2020;63:171–172.
  20. Huang C., Wang Y., Li X., Ren L, Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
  21. Guzik T. J., et al. COVID-19 and the cardiovascular system implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research. 2020. https://doi.org/10.1093/cvr/cvaa106
  22. Xiong T. Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and longterm implications. European Heart Journal. 2020;0:1–3. https://doi.org/10.1093/eurheartj/ehaa231
  23. Kochi A. N., Tagliari A. P., Forleo G. B., Fassini G. M., Tondo C. Cardiac and arrhythmic complications in patients with COVID‐19. J Cardiovasc Electrophysiol. 2020;31:1003–1008. https://doi.org/10.1111/jce.14479
  24. Manish Bansal. Cardiovascular disease and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14:247–250. https://doi.org/10.1016/j.dsx.2020.03.013
  25. Mahmud E., Dauerman H. L., Welt F. G., Messenger J. C., Rao S. V., Grines C., et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Journal of the American College of Cardiology. 2020. https://doi.org/10.1016/j.jacc.2020.04.039
  26. Zheng Y.-Y., Yi M.-T., Zhang J. -Y., Xie X. COVID-19 and the cardiovascular system. Nature reviews. 2020;17:259–260. 27. Thygesen K., Alpert J. S., Jaffe A.S., Chaitman B. R., Bax J. J., Morrow D. A., et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462
  27. Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020. https://doi.org/10.1016/j.jacc.2020.04.031
  28. Long B., Brady W. J., Koyfman A., et al. Cardiovascular complications in COVID-19. American Journal of Emergency Medicine. https://doi.org/10.1016/j.ajem.2020.04.048
  29. Craver R., Huber S., Sandomirsky M., McKenna D., Schieffelin J., Finger L. Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c). =Fetal Pediatr. Pathol. 2020:1–6. https://doi.org/10.1080/15513815.2020.1761491. [Epub ahead of print].
  30. Sala S., Peretto G., Gramegna M., Palmisano A., Villatore A., Vignale D., et al. Acute Myocarditis Presenting as a Reverse Tako-Tsubo Syndrome in a Patient With SARS-CoV-2 Respiratory Infection. Eur. Heart J. 2020;41(19):1861–1862. https://doi.org/10.1093/eurheartj/ehaa286
  31. Liu P. P., Blet A., Smyth D., Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020 Apr 15. https://doi.org/10.1161/CIRCULATIONAHA.120.047549. [Epub ahead of print].
  32. Arentz M., Yim E., Klaff L., et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 [Epub ahead of print]. 34. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. Mar 26 2020;368:m1091.
  33. Das G., Mukherjee N., Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206–1209. https://doi.org/10.1021/acschemneuro.0c00201
  34. Naicker S., Yang C.-W., Hwang S.-J., Liu B.-C., Chen J.-H., Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97:824–828. https://doi.org/10.1016/j.kint.2020.03.001
  35. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
  36. Aragão D.S., Cunha T.S., Arita D.Y., Andrade M.C.C., Fernandes A.B., Watanabe I.K.M., et al. Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture. Int. J. Biol. Macromol. 2011;49:79–84. https://doi.org/10.1016/j.ijbiomac.2011.03.018
  37. Hamming I., Timens W., Bulthuis M. L. C., Lely A. T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. https://doi.org/10.1002/path.1570
  38. Li N., Zimpelmann J., Cheng K., Wilkins J.A., Burns K. D. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1_7 by rat proximal tubules. Am. J. Physiol. Renal. Physiol. 2005;288:F353–F362. https://doi.org/10.1152/ajprenal.00144.2004
  39. Ye M., Wysocki J., William J., Soler M. J., Cokic I., Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 2006;17:3067–3075. https://doi.org/10.1681/ASN.2006050423
  40. Liu H., Jiang Y., Li M., Yu X., Sui D., Fu L. Ginsenoside Rg3 attenuates angiotensin II-mediated renal injury in rats and mice by upregulating angiotensin-converting enzyme 2 in the renal tissue. Evid. Based Complement. Alternat Med. 2019;6741057. https://doi.org/10.1155/2019/6741057
  41. Mizuiri S., Ohashi Y. ACE and ACE2 in kidney disease. World J. Nephrol. 2015;4:74–82. https://doi.org/10.5527/wjn.v4.i1.74
  42. Sharma N., Malek V., Mulay S. R., Gaikwad A. B. Angiotensin II type 2 receptor and angiotensin-converting enzyme 2 mediate ischemic renal injury in diabetic and non-diabetic rats. Life Sci. 2019;235:116796. https://doi.org/10.1016/j.lfs.2019.116796
  43. Oudit G. Y., Herzenberg A. M., Kassiri Z., Wong D., Reich H., Khokha R., et al. Loss of angiotensin-conver ting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol. 2006;168:1808–1820. https://doi.org/10.2353/ajpath.2006.051091
  44. Jessup J. A., Gallagher P. E., Averill D. B., Brosnihan K. B., Tallant E. A., Chappell M. C., Ferrario C. M. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am. J. Physiol. Heart Circ. Physiol. 2006;291:H2166–H2172. https://doi.org/10.1152/ajpheart.00061.2006
  45. van de Veerdonk F., Netea M. G., van Deuren M., van der Meer J. W., de Mast Q., Bruggemann R. J., van der Hoeven H. Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach. Preprints. 2020:2020040023. https://doi.org/10.20944/preprints202004.0023.v1
  46. Cheng H., Wang, Y., & Wang, G. Q. Organ‐protective Effect of Angiotensin‐converting Enzyme 2 and its Effect on the Prognosis of COVID‐19. Journal of Medical Virology. 2020. PMID: 32221983. https://doi.org/10.1002/jmv.25785
  47. Diao B., Feng Z., Wang C., Wang H., Liu L., Wang C., et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Preprint. medRxiv: 2020.03.04:20031120. https://doi.org/10.1101/2020.03.04.20031120
  48. Perico L., Benigni A., Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. In press. https://doi.org/10.1159/000507305
  49. Su H., Yang M., Wan C., Yi L. X., Tang F., Zhu H. Y., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. In press. https://doi.org/10.1016/j.kint.2020.04.003
  50. D’Agati V. D., Kaskel F. J., Falk R. J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 2011;365:2398–2411.
  51. Shkreli M., Sarin K. Y., Pech M. F., et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat Med. 2011;18:111–119.
  52. Larsen C. P., Bourne T. D., Wilson J. D., et al. Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19). Kidney Int Rep. 2020. 55. Peleg Y., Kudose S., D’Agati V., et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020.
  53. Kissling S., Rotman S., Gerber C., et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020.
  54. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–838. https://doi.org/10.1016/j.kint.2020. 03.005.
  55. Nasr S. H., Kopp J. B. COVID-19-Associated Collapsing Glomerulopathy. Kidney Int. Rep. 2020;5:759–761. https://doi.org/10.1016/j.ekir.2020.04.030
  56. Hirsch J. S., Ng J. H., Ross D. W., Sharma P., Shah H. H., Barnett R. L., et al. Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19, Kidney Int. 2020 May 16;S0085–2538(20):30532–30539. https://doi.org/10.1016/j.kint.2020.05.006 Online ahead of print. Kidney Int. 2020. PMID: 32416116
  57. Post A., den Deurwaarder E. S. G., Bakker S. J. L., de Haas R. J., van Meurs M., Gansevoort R. T., Berger S. P. Kidney Infarction in Patients With COVID-19 American Journal of Kidney Diseases. 2020. https://doi.org/10.1053/j.ajkd.2020.05.004
  58. Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges. www.thelancet.com/gastrohep Vol 5 May 2020, Published Online March 4, 2020. https://doi.org/10.1016/S2468-1253(20)30057-1
  59. Ye Z., Song B. COVID-19 related liver injury: call for international consensus. Clinical Gastroenterology and Hepatology. 2020. https://doi.org/10.1016/j.cgh.2020.05.013
  60. Zheng K.I., Gao F., Wang X.-B., Sun Q.-F., Pan K.-H., Wang T.-Y., et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism Clinical and Experimental. 2020. https://doi.org/10.1016/j.metabol.2020.154244
  61. Jinyang Gu, Bing Han, Jian Wang, COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158:1518–1519. https://doi.org/10.1053/j.gastro.2020.02.054
  62. Wang Y., Liu S., Liu H., Li W., Lin F., Jiang L., et al. SARSCoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of Hepatology. 2020. https://doi.org/10.1016/j.jhep.2020.05.002
  63. Tian Y., Rong L., Nian W., He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Alimentary Pharmacology and Therapeutics. 2020;51(9):843–851. https://doi.org/10.1111/apt.15731
  64. Xiao F., Tang M., Zheng X., Liu Y., Li X., & Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833.e3. https://doi.org/10.1053/j.gastro.2020.02.055
  65. Bezzio C., Saibeni S., Variola A., Allocca M., Massari A., Gerardi V., et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study. Gut. 2020:1213–1217. https://doi.org/10.1136/gutjnl-2020-321411
  66. Pal R., Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J. Endocrinol. Invest. 2020. https://doi.org/10.1007/s40618-020-01276-8
  67. Liu F., Long X., Zou W., Fang M., Wu W., Li W., et al. Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection [Internet] [cited 2020 Apr 1].
  68. Ding Y., He L., Zhang Q., Huang Z., Che X., Hou J., et al. Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 2004;203:622–630. https://doi.org/10.1002/path.1560
  69. Yang J. K., Feng Y., Yuan M. Y., Yuan S. Y., Fu H. J., Wu B. Y., et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23:623–628. https://doi.org/10.1111/j.1464-5491.2006.01861
  70. Yang J.-K., Lin S.-S., Ji X.-J., Guo L.-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–199. https://doi.org/10.1007/s00592-009-0109-4.x
  71. Jaeckel E., Manns M., Herrath M. Viruses and diabetes. Ann. N. Y. Acad. Sci. 2006;958:7–25. https://doi.org/10.1111/j.1749-6632.2002.tb02943.x
  72. Wheatland R. Molecular mimicry of ACTH in SARS — implications for corticosteroid treatment and prophylaxis. Med. Hypotheses. 2004;63:855–862. https://doi.org/10.1016/j.mehy.2004.04.009
  73. Xu J., Zhao S., Teng T., Abdalla A.E., Zhu W., Xie L., et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARSCoV. Viruses. 2020;12:244. https://doi.org/10.3390/v12020244
  74. Isidori A. M., Arnaldi G., Boscaro M., Falorni A., Giordano C., Giordano R., et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J. Endocrinol. Invest. 2020. https://doi.org/10.1007/s40618-020-01266-w
  75. Scaroni C., Armigliato M., Cannavò S. COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency? J. Endocrinol. Invest. 2020. https://doi.org/10.1007/s40618-020-01253-1
  76. Porfidia A., Pola R., Porfidia A., et al. Venous thromboembolism in COVID-19 patients. J. Throm. Haemost. 2020. https://doi.org/10.1111//jth.14842
  77. Wei L., Sun S., Xu C., Zhang J., Xu Y., Zhu H., et al. Pathology of the thyroid in severe acute respiratory syndrome. Hum. Pathol. 2007;38:95–102. https://doi.org/10.1016/j.humpath.2006.06.011.
  78. Wei L., Sun S., Xu C., Zhang J., Xu Y., Zhu H., et al. Pathology of the thyroid in severe acute respiratory syndrome. Hum. Pathol. 2007;38:95–102. https://doi.org/10.1016/j.humpath.2006.06.011
  79. Desaillud R., Hober D. Virus and thyroiditis: an update. Virol. J. 2009;6:5. https://doi.org/10.1186/1743-422X-6-5
  80. Bellastella G., Maiorino M. I., Esposito K. Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands? Endocrinol. Invest. 2020. https://doi.org/10.1007/s40618-020-01311-8
  81. Liang Y., Wang M.-L., Chien C.-S., Yarmishyn A. A., Yang Y.-P., Lai W.-Y., et al. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Front. Immunol. 2020;11:1022.
  82. Lega S., Naviglio S., Volpi S., Tommasini A. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. Vaccines. 2020;8:224–254. https://doi.org/10.3390/vaccines8020224
  83. Zheng M., Gao Y., Wang G., Song G., Liu S., Sun D., et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. 2020;17:533–5. https://doi.org/10.1038/s41423-020-0402-2
  84. Zeng Q., Li Y., Huang G., Wu W., Dong S., Xu Y. Mortality of COVID-19 is associated with cellular immune function compared to immune function in Chinese Han population. Medrxiv. 2020. https://doi.org/10.1101/2020.03.08.20031229
  85. Zheng J. SARS-CoV-2: An Emerging Coronavirus that Causes a Global Threat. Int. J. Biol. Sci. 2020;16:1678–1685. [CrossRef]
  86. Wang X., Xu W., Hu G., Xia S., Sun Z., Liu Z., et al. SARSCoV-2 infects T lymphocytes through its spike proteinmediated membrane fusion. Cell Mol. Immunol. 2020;1–3. https://doi.org/10.1038/s41423-020-0424-9
  87. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia inWuhan, China: A descriptive study. Lancet. 2020;395:507–513. [CrossRef]
  88. Wang D., Hu B., Hu, C., Zhu F., Liu X., Zhang J., et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. [CrossRef]
  89. Wang X., Xu W., Hu G., Xia S., Sun Z., Liu Z., et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell. Mol. Immunol. 2020;1–3. [CrossRef]
  90. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. Dermatol. Venereol. 2020. http://dx.doi.org/10.1111/jdv.16387 [Epub ahead of print].
  91. Sachdeva M., Gianottibc R., Shhaha M., Lucia B., Tosi D., Veraldic S., et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J. Dermatol. Sci. 2020). https://doi.org/10.1016/j. jdermsci.2020.04.011
  92. Gianotti R. COVID 19 and the skin-heuristic review, Dermo Sprint. 2020. April 06. In press.
  93. Manalo I. F., Smith M. K., Cheeley J., Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J. Am. Acad. Dermatol. 2020. http://dx.doi.org/10.1016/j.jaad.2020.04.018 [Epub ahead of print].
  94. Magro C., Mulvey J., Berlin D., Nuovo G., Salvatore S., Harp J., et al. Complementary associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl. Res. 2020. In press.
  95. Ayala E., Kagawa F. T., Wehner J. H., Tam J., Upadhyay D. Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA. 2009;302:1863–1864. https://doi.org/10.1001/jama.2009.1582
  96. Jin Min & Tong Qiaoxia. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerging infectious diseases. 2020. https://doi.org/10.3201/eid2607.200445
  97. Lahiri D., Ardila A. COVID-19 Pandemic: A Neurological Perspective. Cureus. 2020;12(4):e7889. https://doi.org/10.7759/cureus.7889
  98. Xu J., Qi L., Chi X. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol. Reprod. 2006;74:410– 416. [PMC free article] [PubMed] [Google Scholar]
  99. Ding Y., He L., Zhang Q. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 2004;203:622–630. [PMC free article] [PubMed] [Google Scholar]
  100. Fan C., Li K., Ding Y., Lu W., Wang JACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. medRxiv. 2020.
  101. Shen Q., Xiao X., Aierken A., Liao M., Hua J. The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection. medRxiv. 2020
  102. Song C., Wang Y., Li W., Hu B., Chen G., Xia P., et al. https://doi.org/10.1101/2020.03.31.20042333
  103. Li R., Yin T., Fang F., Li Q., Chen J., Wang Y., et al. Potential risks of SARS-CoV-2 infection on reproductive health. ReproductiveBioMedicine. 2020 (Onlinehttps:// doi.org/). https://doi.org/10.1016/j.rbmo.2020.04.018
  104. di Mascio D., Khalil A., Saccone G., Nappi L., Scambia G., Berghella V., D’Antonio F. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1–19) during pregnancy: a systematic review and meta-analysis. [Published online ahead of print, 2020 Mar 25]. American Journal of Obstetrics and Gynecology. MFM. 2020;100107. https://doi.org/10.1016/j.ajogmf.2020.100107
  105. Schwartz D. A., Graham A. L. Potential maternal and infant outcomes from Coronavirus 2019-nCoV (SARSCoV-2) infecting pregnant women: Lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194. https://doi.org/10.3390/v12020194
  106. Ferrazzi E. M., Frigerio L., Cetin I., Vergani P., Spinillo A., Prefumo F., et al. COVID-19 Obstetrics Task Force, Lombardy, Italy: executive management summary and short report of outcome. International Journal of Gynecology and Obstetrics. 2020. [Published online ahead of print, 2020 Apr 8]. https://doi.org/10.1002/ijgo.13162
  107. Conaldi P. G., et al. Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J. Virol. 1997;71(12):9180–9187.
  108. Nowakowski T. J., et al. Expression Analysis Highlights AXL as a Candidate Zika Virus Entry Receptor in Neural Stem Cells. Cell Stem. Cell. 2016;18(5):591–596.
  109. Jayawardena N., et al. Virus-Receptor Interactions: Structural Insights for Oncolytic Virus Development. Oncolytic Virother. 2019;8:39–56.
  110. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children — United States, February 12 — April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422.
  111. Dong Y., Mo X., Hu Y., et al. Epidemiology of COVID-19 among Children in China. Pediatrics 2020; 145.
  112. Zimmermann P., Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect Dis J. 2020;39:355.
  113. McCrindle B. W., Rowley A. H., Newburger J. W., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–e999. https://doi.org/10.1161/CIR.0000000000000484

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Коган Е.А., Березовский Ю.С., Проценко Д.Д., Багдасарян Т.Р., Грецов Е.М., Демура С.А., Демяшкин Г.А., Калинин Д.В., Куклева А.Д., Курилина Э.В., Некрасова Т.П., Парамонова Н.Б., Пономарев А.Б., Раденска-Лоповок С.Г., Семенова Л.А., Тертычный А.С., 2020

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60835 выдано 09.09.2021 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 – 59181 выдано 03.09.2014 г.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах